Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Watch for Mirati Therapeut to Potentially Pullback After Gaining 33.10% Yesterday

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $102.43 to a high of $106.31. Yesterday, the shares gained 33.1%, which took the trading range above the 3-day high...

MRTX : 104.33 (+1.11%)
Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in combination...

MRTX : 104.33 (+1.11%)
Noteworthy Tuesday Option Activity: MRTX, R, GPRE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Mirati Therapeutics Inc , where a total volume of 5,862 contracts has been traded thus...

MRTX : 104.33 (+1.11%)
R : 53.45 (-0.89%)
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of -8.66% and 97.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

MRTX : 104.33 (+1.11%)
Mirati: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Monday reported a loss of $54.3 million in its third quarter.

MRTX : 104.33 (+1.11%)
Mirati Therapeutics Reports Third Quarter 2019 Financial Results

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2019.

MRTX : 104.33 (+1.11%)
Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the first clinical results from its Phase 1/2 trial evaluating MRTX849, an investigational KRAS G12C...

MRTX : 104.33 (+1.11%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (AMAG , MRTX, ARWR, AIMT , BMRN )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AMAG : 9.21 (-0.43%)
MRTX : 104.33 (+1.11%)
ARWR : 45.25 (-0.07%)
Mirati Therapeut Set to Possibly Pullback After Yesterday's Rally of 2.94%

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $75.95 to a high of $83.38. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high...

MRTX : 104.33 (+1.11%)
Shares of MRTX Down 5.7% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Mirati Therapeut (NASDAQ:MRTX) on September 30th, 2019 at $80.63. In approximately 3 weeks, Mirati Therapeut has returned 5.66% as of today's recent price of $76.06....

MRTX : 104.33 (+1.11%)
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that the Company will have two presentations at the Society for Immunotherapy of Cancer (SITC) 34th Annual...

MRTX : 104.33 (+1.11%)
Downtrend Call Working As Mirati Therapeut Stock Falls 4.6% (MRTX)

SmarTrend identified a Downtrend for Mirati Therapeut (NASDAQ:MRTX) on September 30th, 2019 at $80.63. In approximately 2 weeks, Mirati Therapeut has returned 4.58% as of today's recent price of $76.93....

MRTX : 104.33 (+1.11%)
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present pre-clinical data and initial clinical data on MRTX849, a novel and optimized KRAS...

MRTX : 104.33 (+1.11%)
Look for Shares of Mirati Therapeut to Potentially Pullback after Yesterday's 1.77% Rise

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $72.89 to a high of $74.86. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high...

MRTX : 104.33 (+1.11%)
Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

MRTX : 104.33 (+1.11%)
Mirati Therapeut Falls 6.11% on Heavy Volume: Watch For Potential Rebound

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $78.46 to a high of $87.37. Yesterday, the shares fell 6.1%, which took the trading range below the 3-day low of...

MRTX : 104.33 (+1.11%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , ADMS , MRTX, CHRS , RTRX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ADMS : 5.41 (+0.37%)
STML : 9.60 (-1.54%)
MRTX : 104.33 (+1.11%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (AIMT , ARWR, LJPC , MRTX, AGIO )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AIMT : 28.32 (unch)
LJPC : 6.69 (-0.89%)
ARWR : 45.25 (-0.07%)
MRTX : 104.33 (+1.11%)
Mirati Therapeut Has Returned 15.1% Since SmarTrend Recommendation (MRTX)

SmarTrend identified a Downtrend for Mirati Therapeut (NASDAQ:MRTX) on July 26th, 2019 at $97.26. In approximately 2 months, Mirati Therapeut has returned 15.14% as of today's recent price of $82.53.

MRTX : 104.33 (+1.11%)
Mirati Therapeut Rises 4.62% on Heavy Volume: Watch For Potential Pullback

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $86.00 to a high of $93.89. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high...

MRTX : 104.33 (+1.11%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -0.45 , AIZ +1.53 , SBAC -2.23 , SO +0.22 , WELL -0.82
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar